

# Nina Ditsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1005742/publications.pdf>

Version: 2024-02-01

54  
papers

5,536  
citations

331670

21  
h-index

175258

52  
g-index

54  
all docs

54  
docs citations

54  
times ranked

9809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014, 384, 164-172.	13.7	3,224
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
3	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
4	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
5	Prevalence of <i>BRCA1/2</i> germline mutations in 21â€¦401 families with breast and ovarian cancer. <i>Journal of Medical Genetics</i> , 2016, 53, 465-471.	3.2	179
6	Gene panel testing of 5589 <i>BRCA1/2</i> negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Cancer Medicine</i> , 2018, 7, 1349-1358.	2.8	126
7	Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification. <i>Human Mutation</i> , 2019, 40, 1557-1578.	2.5	102
8	The Association between Vitamin D Receptor Expression and Prolonged Overall Survival in Breast Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2012, 60, 121-129.	2.5	85
9	Association Between Loss-of-Function Mutations Within the <i>FANCM</i> Gene and Early-Onset Familial Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1245.	7.1	74
10	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
11	Thyroid function in breast cancer patients. <i>Anticancer Research</i> , 2010, 30, 1713-7.	1.1	39
12	Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. <i>Journal of Translational Medicine</i> , 2016, 14, 112.	4.4	38
13	Thyroid hormone receptor (TR)alpha and TRbeta expression in breast cancer. <i>Histology and Histopathology</i> , 2013, 28, 227-37.	0.7	35
14	Thyroid Hormone Receptors Predict Prognosis in <i>BRCA1</i> Associated Breast Cancer in Opposing Ways. <i>PLoS ONE</i> , 2015, 10, e0127072.	2.5	32
15	How and for whom are decision aids effective? Long-term psychological outcome of a randomized controlled trial in women with newly diagnosed breast cancer.. <i>Health Psychology</i> , 2011, 30, 12-19.	1.6	29
16	Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1637-1647.	2.5	29
17	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. <i>Annals of Surgical Oncology</i> , 2019, 26, 3892-3901.	1.5	29
18	The <i>FANCM</i> :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28

#	ARTICLE	IF	CITATIONS
19	Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study. <i>BMC Cancer</i> , 2015, 15, 519.	2.6	26
20	Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor $\beta$ are overexpressed in BRCA1 mutated breast cancer and predict prognosis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 57.	8.6	24
21	The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1016.	4.1	24
22	Neoadjuvant radiotherapy followed by mastectomy and immediate breast reconstruction. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 324-331.	2.0	23
23	Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 1135-1144.	1.7	22
24	Expression of Thyroid Hormone Receptors in Villous Trophoblasts and Decidual Tissue at Protein and mRNA Levels Is Downregulated in Spontaneous and Recurrent Miscarriages. <i>Journal of Histochemistry and Cytochemistry</i> , 2015, 63, 511-523.	2.5	21
25	Cancer surveillance and distress among adult pathogenic <i>TP53</i> germline variant carriers in Germany: A multicenter feasibility and acceptance survey. <i>Cancer</i> , 2020, 126, 4032-4041.	4.1	20
26	Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma. <i>Oncology Letters</i> , 2012, 4, 665-671.	1.8	19
27	Cytoplasmic PPAR $\beta$ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. <i>Journal of Translational Medicine</i> , 2020, 18, 94.	4.4	19
28	High Galectin-7 and Low Galectin-8 Expression and the Combination of both are Negative Prognosticators for Breast Cancer Patients. <i>Cancers</i> , 2020, 12, 953.	3.7	17
29	Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses. <i>Endocrine Connections</i> , 2018, 7, 749-761.	1.9	16
30	Expression of H3K4me3 and H3K9ac in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2017-2027.	2.5	16
31	Placental Galectin-2 Expression in Gestational Diabetes: A Systematic, Histological Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2404.	4.1	16
32	EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer. <i>BMC Cancer</i> , 2018, 18, 431.	2.6	15
33	Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX $\alpha$ is an independent prognostic marker for breast cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 50.	8.6	14
34	A retrospective investigation of women's experience with breast reconstruction after mastectomy. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 555-561.	1.7	13
35	Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 87-97.	1.8	13
36	Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor $\beta$ 1 Are Inversely Associated with Survival in Primary Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 330.	4.1	13

#	ARTICLE	IF	CITATIONS
37	&lt;p&gt;EP3 receptor antagonist L798,106 reduces proliferation and migration of SK-BR-3 breast cancer cells&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6053-6068.	2.0	12
38	The Prognostic Impact of Retinoid X Receptor and Thyroid Hormone Receptor alpha in Unifocal vs. Multifocal/Multicentric Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 957.	4.1	12
39	The expression of thyroid hormone receptors (THR) is regulated by the progesterone receptor system in first trimester placental tissue and in BeWo cells in vitro. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 195, 31-39.	1.1	11
40	p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1163-1170.	2.5	9
41	Prognostic relevance of RIP140 and ERÎ² expression in unifocal versus multifocal breast cancers: a preliminary report. <i>International Journal of Molecular Sciences</i> , 2019, 20, 418.	4.1	8
42	Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1923-1932.	2.5	8
43	L-Dopa-Decarboxylase (DDC) Is a Positive Prognosticator for Breast Cancer Patients and Epinephrine Regulates Breast Cancer Cell (MCF7 and T47D) Growth In Vitro According to Their Different Expression of Gi- Protein- Coupled Receptors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9565.	4.1	7
44	Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). <i>Breast Cancer Research</i> , 2021, 23, 45.	5.0	7
45	Cytoplasmic Localization of RXRÎ± Determines Outcome in Breast Cancer. <i>Cancers</i> , 2021, 13, 3756.	3.7	7
46	Off-label use in germany - a current appraisal of gynaecologic university departments. <i>European Journal of Medical Research</i> , 2011, 16, 7.	2.2	6
47	Germline RAD51C mutations confer susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2012, 44, 476-476.	21.4	6
48	The role of E-Cadherin expression in primary site of breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 913-920.	1.7	5
49	Evaluation of Reproductive Concerns and Biographical Impact of Breast Cancer in Young Patients. <i>Breast Care</i> , 2018, 13, 124-128.	1.4	4
50	EP3 Is an Independent Prognostic Marker Only for Unifocal Breast Cancer Cases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4418.	4.1	3
51	First Evidence for a Role of Siglec-8 in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2000.	4.1	3
52	Subcellular Distribution of Thyroid Hormone Receptor Beta in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2698.	4.1	3
53	Evaluation of the anti-Thomsenâ€Friedenreich antibodies Nemo-TF1 and Nemo-TF2 as prognostic markers in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 643-652.	2.5	0
54	Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes. <i>Anticancer Research</i> , 2016, 36, 3185-90.	1.1	0